Divis Laboratories Ltd (DIVISLAB) is currently trading at 10,305.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Divi's Laboratories is a leading integrated Indian API manufacturer and CDMO producing active pharmaceutical ingredients, intermediates and nutraceutical ingredients across six manufacturing units with a global presence in roughly 100 countries; exports comprise about 90% of standalone revenue, with Europe and North America accounting for approximately 75% of export sales. For Q1 FY27 the company reported consolidated total income of ₹3,144 crore, standalone revenue of ₹3,037 crore, profit before tax of ₹1,180 crore and profit after tax of ₹902 crore, driven by Custom Synthesis contributing roughly 60% of revenue and Generics around 40%, reflecting validation activity and early commercial flows across several projects. Divi's is executing three major capex programmes totalling about ₹2,000 crore that are nearing completion with ~70% capitalized, capitalized assets of ₹451 crore and CWIP of ₹2,034 crore as of June 30, 2026; Unit‑3 at Kakinada is positioned as a backward‑integration hub to support pre‑chemistry operations and network flexibility across Units 1 and 2. Peptides are a strategic growth pillar: Divi's opened a Peptide Centre of Excellence, is expanding both solid‑phase and liquid‑phase peptide synthesis capabilities, installing large SPPS reactors and building upstream capabilities such as protected amino acids and resins to establish a vertically integrated, scalable peptide manufacturing platform. Management has prioritized supply continuity amid West Asia geopolitical stress, adopting a three‑month rolling inventory policy for critical solvents, while investing in process technologies such as continuous flow, biocatalysis and automation to improve safety, yield and sustainability across complex chemistries.

Over the past 52 weeks, Divis Laboratories Ltd has traded between a low of ₹5,648.00 and a high of ₹10,305.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Divis Laboratories Ltd has a market capitalization of approximately 2,73,565.37. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Divis Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 93.53 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 2,73,565.37 Cr, Divis Laboratories Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Divis Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Divis Laboratories Ltd is 93.53. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Divi's Laboratories reported profit before tax of Rs 2,685 crore for the half year ended 30 September 2026 but net operating cash inflow of Rs 384 crore. Operating assets absorbed Rs 2,642 crore of cash, while operating liabilities supplied a smaller Rs 648 crore offset. Income taxes paid were Rs 575 crore.

Divi's Laboratories reported consolidated profit of Rs 1,127 crore for the quarter ended September 30, 2026. This was 64% higher than Rs 689 crore in the quarter ended September 30, 2025. Basic earnings per share were Rs 42.49, compared with Rs 25.97 a year earlier.

Divi's Laboratories reported revenue from operations of ₹3,080 crore for the quarter ended June 30, 2026. This was 27.8% higher than ₹2,410 crore in Q1 FY26 and 8.8% above the March 2026 quarter.

The earnings conference call is scheduled for August 01, 2026 at 14:00 IST to discuss the quarter ended June 30, 2026 (Q1 FY27).